Entrectinib in the treatment of patients with ROS1‑positive advanced non‑small cell lung cancer
MUDr. Leona Koubková
Pneumologická klinika 2. LF UK a FN v Motole, Praha
In recent years, we have witnessed the expanding possibilities of genotyping tumors, which allows us to strengthen precision medicine, the essence of which is the pursuit of individualized treatment. There is also an increase in the number of drugs that enable molecularly targeted therapy of tumors with proven genetic aberrations. These include entrectinib, which is effective in patients with non-small cell lung cancer who have been shown to rebuild the ROS1 gene or fuse the NTRK gene, even with metastatic central nervous system involvement.
non-small cell lung cancer, targeted treatment, ROS1, NTRK, entrectinib
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...